• トップページ
  • 診療のご案内
  • センターのご紹介
  • 当施設について
  • 診療関連部門診療科のご案内
  • 採用案内

埼玉県立がんセンター > 論文リスト > 2017年度の論文リスト

ここから本文です。

 

掲載日:2019年6月14日

2017年度の論文リスト

 各年度の論文リスト

 ※ボタンをクリックすると年度ごとに一覧を参照できます

2017年度の論文リスト

Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.
Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J.
Oncotarget. 2017 Nov 18;8(64):107513-107529. doi: 10.18632/oncotarget.22495.

Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes.
Su Z, Kishida S, Tsubota S, Sakamoto K, Cao D, Kiyonari S, Ohira M, Kamijo T, Narita A, Xu Y, Takahashi Y, Kadomatsu K.
Oncotarget. 2017 Nov 15;8(63):106296-106310. doi: 10.18632/oncotarget.22435

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.
Li Y*, Ohira M*, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A. (*co-1st)
Oncotarget. 2017 May 23;8(34):56684-56697. doi: 10.18632/oncotarget.18079.

CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T.
Oncotarget. 2017 8(28):45046-45059. doi: 10.18632/oncotarget.18464.

Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer.
Sun Y, Harada M, Shimozato O, Souda H, Takiguchi N, Nabeya Y, Kamijo T, Akita H, Anzai N, Chiba K, Furihata T.
Biomark Med. 2017 Aug;11(8):629-639. doi: 10.2217/bmm-2017-0098.

Similar articles Effects of catechins and caffeine on the development of atherosclerosis in mice.
Liu L, Nagai I, Gao Y, Matsushima Y, Kawai Y, Sayama K.
Biosci Biotechnol Biochem. 2017;81:1948-1955. doi: 10.1080/09168451.2017.1364618.

Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.
J Natl Cancer Inst. 2017 109. doi: 10.1093/jnci/djx062.

PRC2-mediated transcriptomic alterations at the embryonic stage govern tumorigenesis and clinical outcome in MYCN-driven neuroblastoma.
Tsubota S, Kishida S, Shimamura T, Ohira M, Yamashita S, Cao D, Kiyonari S, Ushijima T, Kadomatsu K.
Cancer Res 2017 77:5259-5271. doi: 10.1158/0008-5472.CAN-16-3144.

Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H.
Gynecologic Oncology 2017 144 :377-383. doi: 10.1016/j.ygyno.2016.11.045.

BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.
Genes Chromosomes Cancer. 2017 56:405-420. doi: 10.1002/gcc.22445.

Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance.
Tsuboi K, Nagatomo T, Gohno T, Higuchi T, Sasaki S, Fujiki N, Kurosumi M, Takei, H, Yamaguchi Y, Niwa T, Hayashi S.
J Steroid Biochem Mol Biol. 2017 171: 209-217. DOI: 10.1016/j.jsbmb.2017.04.001

Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells.
Niwa T, Shinagawa Y, Asari Y, Suzuki K, Takanobu J, Gohno T, Yamaguchi Y, Hayashi S.
J Steroid Biochem Mol Biol. 2017, 165: 448-457. DOI: 10.1016/j.jsbmb.2016.09.008

Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.
J Human Genetics, 2017, 62(1):15-24. DOI: 10.1038/jhg.2016.89

Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, Yamaguchi Y, Niwa T, Hayashi S.
J Steroid Biochem Mol Biol. 2017, 167: 115-125. DOI: 10.1016/j.jsbmb.2016.11.017

Conjugation of two RNA aptamers improves binding affinity to AML1 Runt domain.
Nomura Y, Yamazaki K, Amano R, Takada K, Nagata T, Kobayashi N, Tanaka Y, Fukunaga J, Katahira M, Kozu T, Nakamura Y, Haishima Y, Torigoe H, Sakamoto T.
J Biochem. 2017 162:431-436. DOI: 10.1093/jb/mvx049

NMR monitoring of the SELEX process to confirm enrichment of structured RNA.
Amano R, Aoki K, Miyakawa S, Nakamura Y, Kozu T, Kawai G, Sakamoto T.
Sci Rep. 2017 7:283. DOI: 10.1038/s41598-017-00273-x

Inhibition of TNF-α-interacting protein α (Tipα)-associated gastric carcinogenesis by BTG2/TIS21 via downregulating cytoplasmic nucleolin expression.
Devanand P, Oya Y, Sundaramoorthy S, Song KY, Watanabe T, Kobayashi Y, Shimizu Y, Hong SA, Suganuma M, Lim IK.
Exp. Mol. Med. 2018 50: e449; doi:10.1038/emm.2017. 281.

Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
Iida K, Sakai, R, Yokoyama S, Kobayashi N, Togo S, Yoshikawa H Y, Rawangkan A, Namiki K, Suganuma M.
Sci. Rep. 2017 7:17770. doi: 10.1038/s41598-017-18120-4.

A single-round selection of selective DNA aptamers for mammalian cells by polymer-enhanced capillary transient isotachophoresis.
Hirose K, Tsuchida M, Asakura H, Wakui H, Yohimoto K, Iida K, Sato M, Shibukawa M, Suganuma M, Saito, S.
Analyst. 2017 142: 3997-4152. DOI: 10.1039/c7an00909g

Adsorption of galloyl catechin aggregates significantly modulates membrane mechanics in the absence of biochemical cues.
Matsuzaki T, Ito H, Chevyreva V, Makky A, Kaufmann S, Okano K, Kobayashi N, Suganuma M, Nakabayashi N, Yoshikawa H Y, Tanaka M.
Phys. Chem. Chem. Phys. 2017 19(30): 19937-19947. DOI: 10.1039/c7cp02771k

Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic
enhancement of apoptosis in human lung cancer cells treated with the combination of
a synthetic retinoid, Am80 and green tea catechin.
Oya Y. Mondal A, Rawangkan A, Umsumarng S, Iida K, Watanabe T, Kanno M, Suzuki K, Li Z, Kagechika H, Shudo K, Fujiki H, Suganuma M.
J. Nutri. Biochem. 2017 42: 7-16, doi: 10.1016/j.jnutbio.2016.12.015.

デヴィータ がんの分子生物学 第2版, 23章 小児がんの分子生物学 (翻訳)
Cancer -Principles & Practice of Oncology- 2nd edition (著Vincent T. DeVita, Jr., Theodore S.Lawrence, Steven A. Rosenberg)
大平美紀、監訳 宮園浩平、石川冬木、間野博行 
メディカル・サイエンス・インターナショナル2017年5月29日発行pp.421-438.

お問い合わせ

病院局 がんセンター  

郵便番号362-0806 埼玉県北足立郡伊奈町小室780番地 埼玉県立がんセンター

ファックス:048-722-1129

より良いウェブサイトにするためにみなさまのご意見をお聞かせください

このページの情報は役に立ちましたか?

このページの情報は見つけやすかったですか?